Meeting
2020 ASCO Virtual Scientific Program
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
Authors
Sumanta K. Pal
City of Hope Comprehensive Cancer Center, Duarte, CA
Sumanta K. Pal , Bernard Escudier , Michael B. Atkins , Thomas E. Hutson , Camillo Porta , Elena Verzoni , Michael N. Needle , David F. McDermott , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
02627963
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5062)
DOI
10.1200/JCO.2020.38.15_suppl.5062
Abstract #
5062
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2022 ASCO Genitourinary Cancers Symposium
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
First Author: Jonathan Heseltine
Poster
2017 ASCO Annual Meeting
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini
Poster
2021 ASCO Annual Meeting
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).
First Author: Elena Verzoni